Suppr超能文献

罗伊氏乳杆菌对预防小鼠哮喘模型的影响。

The Effects of Lactobacillus rhamnosus on the Prevention of Asthma in a Murine Model.

机构信息

Department of Pediatrics, Childhood Asthma Atopy Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

出版信息

Allergy Asthma Immunol Res. 2010 Jul;2(3):199-205. doi: 10.4168/aair.2010.2.3.199. Epub 2010 Mar 19.

Abstract

PURPOSE

Lactobacilli are probiotic bacteria that are effective in the management of allergic diseases or gastroenteritis. It is hypothesized that such probiotics have immunoregulatory properties and promote mucosal tolerance. Our goal was to investigate whether Lactobacillus casei rhamnosus Lcr35 could inhibit airway inflammation in an ovalbumin (OVA)-induced murine model of asthma.

METHODS

BALB/c mice aged 6 weeks were used in the present study. Lactobacillus casei rhamnosus Lcr35 was administered daily, starting 1 week prior to the first OVA sensitization (group 1) and 2 days before the first 1% OVA airway challenge (group 2). Mice that received only saline at both sensitization and airway challenge time points were used as negative controls (group 3), and those that had OVA-induced asthma were used as positive controls (group 4). Airway responsiveness to methacholine was assessed, and bronchoalveolar lavage (BAL) was performed. At the endpoint of the study, total IgE as well as OVA-specific IgE, IgG(1) and IgG(2a) in serum was measured by enzyme-linked immunosorbent assay. Lung pathology was also evaluated.

RESULTS

Airway hyperresponsiveness, total cell counts and the proportion of eosinophils in BAL fluid were significantly decreased in group 1 compared with group 4 (P<0.05). Total serum IgE levels were also significantly decreased in group 1 compared with group 4. Serum levels of OVA-specific IgE, IgG(1) and IgG(2a) were not significantly influenced by treatment with Lcr35. There was significantly less peribronchial and perivascular infiltration of inflammatory cells in group 1 compared with group 4; however, there were no significant differences in methacholine challenge, BAL, serology or histology between groups 2 and 4.

CONCLUSIONS

Oral treatment with Lcr35 prior to sensitization can attenuate airway inflammation and hyperreactivity in a mouse model of allergic airway inflammation. These results suggest that Lcr35 may have potential for preventing asthma.

摘要

目的

乳杆菌是一种益生菌,可有效治疗过敏疾病或肠胃炎。据推测,这种益生菌具有免疫调节特性,并促进黏膜耐受。我们的目标是研究干酪乳杆菌 Lcr35 是否可以抑制卵清蛋白(OVA)诱导的哮喘小鼠模型中的气道炎症。

方法

本研究使用 6 周龄 BALB/c 小鼠。干酪乳杆菌 Lcr35 于首次 OVA 致敏前 1 周(第 1 组)和首次 1%OVA 气道攻击前 2 天(第 2 组)开始每日给药。仅在致敏和气道攻击时给予生理盐水的小鼠作为阴性对照(第 3 组),而 OVA 诱导哮喘的小鼠作为阳性对照(第 4 组)。通过乙酰甲胆碱评估气道反应性,并进行支气管肺泡灌洗(BAL)。在研究终点,通过酶联免疫吸附试验测量血清总 IgE 以及 OVA 特异性 IgE、IgG(1)和 IgG(2a)。还评估了肺病理学。

结果

与第 4 组相比,第 1 组气道高反应性、BAL 液中的总细胞计数和嗜酸性粒细胞比例显著降低(P<0.05)。第 1 组血清总 IgE 水平也显著低于第 4 组。Lcr35 治疗对血清 OVA 特异性 IgE、IgG(1)和 IgG(2a)水平没有显著影响。与第 4 组相比,第 1 组支气管和血管周围炎性细胞浸润明显减少;然而,第 2 组和第 4 组之间在乙酰甲胆碱激发、BAL、血清学或组织学方面没有显著差异。

结论

致敏前口服 Lcr35 治疗可减轻变应性气道炎症小鼠模型中的气道炎症和高反应性。这些结果表明 Lcr35 可能具有预防哮喘的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a900/2892053/9acac0ad6b5e/aair-2-199-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验